Published in Eur J Drug Metab Pharmacokinet on July 02, 2004
A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos (2010) 0.92
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med (2016) 0.87
Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain. ACS Med Chem Lett (2015) 0.79
Mucosal and blood-brain barrier transport kinetics of the plant N-alkylamide spilanthol using in vitro and in vivo models. BMC Complement Altern Med (2016) 0.78
Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling. Theor Biol Med Model (2008) 0.78
Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. Bioorg Med Chem Lett (2015) 0.76
PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance. Pharm Res (2016) 0.75
Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats. BMC Cancer (2016) 0.75
Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry (2006) 0.95
Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res (2013) 0.92
Alternative functional in vitro models of human intestinal epithelia. Front Pharmacol (2013) 0.90
Biotin-ubiquitin tagging of mammalian proteins in Escherichia coli. Protein Expr Purif (2003) 0.90
Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos (2006) 0.88
Cone voltage induced in-source dissociation of glucuronides in electrospray and implications in biological analyses. Rapid Commun Mass Spectrom (2003) 0.87
Structural basis for elastolytic substrate specificity in rodent alpha-chymases. J Biol Chem (2007) 0.82
Screening for reactive intermediates and toxicity assessment in drug discovery. Curr Opin Drug Discov Devel (2006) 0.82
Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol (2006) 0.80
Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists. Bioorg Med Chem Lett (2004) 0.79
Improved pharmacokinetic and bioavailability support of drug discovery using serial blood sampling in mice. J Pharm Sci (2009) 0.79
Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists. J Med Chem (2006) 0.79
ADME optimization and toxicity assessment in early- and late-phase drug discovery. Curr Top Med Chem (2009) 0.78
The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens. Eur J Drug Metab Pharmacokinet (2005) 0.78
Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors. Rapid Commun Mass Spectrom (2010) 0.77
Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. Clin Exp Pharmacol Physiol (2006) 0.77
Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg Med Chem Lett (2004) 0.77
The IC(50) concept revisited. Curr Top Med Chem (2012) 0.76
The application of nuclear magnetic resonance-based metabonomics to the dominant-submissive rat behavioral model. Anal Biochem (2005) 0.75
Discovery of a dihydropyrimidine series of molecules that selectively mimic the biological actions of calcitonin. Bioorg Med Chem Lett (2004) 0.75
Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists. Bioorg Med Chem Lett (2004) 0.75
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity. Bioorg Med Chem Lett (2002) 0.75
Distribution and metabolism of the antipsychotic agent mazapertine succinate in rats. J Pharm Biomed Anal (2005) 0.75
Evaluation of the effect of oxygen exposure on human liver microsomal metabolism of mitomycin C in the presence of glutathione using liquid chromatography-quadrupole time of flight mass spectrometry. Anal Biochem (2005) 0.75
The synthesis and evaluation of 10- and 12-membered ring benzofused enediyne amino acids. Bioorg Med Chem (2005) 0.75
Investigation of vesicle electrokinetic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drug candidates. Electrophoresis (2006) 0.75
Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists. Bioorg Med Chem Lett (2003) 0.75